Inspira Technologies Oxy B.H.N. Ltd. Warrant - IINNW STOCK NEWS

Welcome to our dedicated page for Inspira Technologies Oxy B.H.N. Ltd. Warrant news (Ticker: IINNW), a resource for investors and traders seeking the latest updates and insights on Inspira Technologies Oxy B.H.N. Ltd. Warrant stock.

Inspira Technologies Oxy BHN Ltd is a specialty medical device company focused on developing innovative respiratory support technology as an alternative to mechanical ventilation. By 2020, over 600,000 patients in the U.S. will need mechanical ventilation, with a significant portion requiring ICU admission, costing an estimated $64 billion annually. The company's OxyLink technology, an advanced nano vesicle device, introduces an intravascular oxygenation system to enhance blood oxygen levels and reduce carbon dioxide, enabling physicians to address primary ventilatory conditions effectively.

The company has recently received 510(k) class II clearance from the U.S. FDA for its INSPIRA ART100 Cardiopulmonary Bypass System. Inspira Technologies aims to revolutionize the respiratory care market with its innovative products, including the INSPIRA ART (Gen 2) system designed to elevate patient oxygen levels and potentially reduce the need for mechanical ventilation, providing new treatment alternatives and enhancing patient care.

04/25/2024 08:00 AM

News

Inspira™ Receives CSA Certification of Compliance to U.S. Standards for the INSPIRA™ ART100

Rhea-AI Summary

Inspira™ Technologies OXY B.H.N. (Nasdaq: IINN) has received the Canadian Standards Association (CSA) Certification of Compliance to U.S. standards for the INSPIRA ART100 device. This certification marks a significant step towards market access for their medical device, showcasing adherence to strict safety and performance requirements.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-18.21%

Tags

04/16/2024 08:42 AM

News

Inspira™ Signs Term Sheet for Use of INSPIRA™ ART100 Device in Organ Transplant Procedures

Rhea-AI Summary

Inspira™ Technologies OXY B.H.N. signs a term sheet with Beilinson Hospital in Israel for the evaluation of its INSPIRA ART100 device in organ transplant procedures. Beilinson Hospital, a leading organ transplant center in Israel, will provide data and feedback for the evaluation. The collaboration aims to enhance patient outcomes and expand the use of the device in medical settings.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

0.79%

Tags

04/10/2024 08:24 AM

News

Inspira™ and Ennocure In Vitro Study Results Show 100% Prevention of Bacterial Growth that Causes Bloodstream Infections

Rhea-AI Summary

Inspira Technologies and Ennocure MedTech announce successful results in developing a bio-electronic treatment to prevent bloodstream infections, showing a 75% reduction in bacterial growth within 4 hours and 100% reduction within 24 hours. The technology aims to inhibit bacterial proliferation without the use of antiseptic agents, potentially offering advantages over current standard care solutions.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

9.37%

Tags

04/03/2024 08:30 AM

News

Inspira™ Announces Program to Pioneer the Applicable Use of the INSPIRA™ ART100 Device for an Artificial Womb

Rhea-AI Summary

Inspira Technologies OXY B.H.N. announces the exploration of INSPIRA ART100 Device for neonatal respiratory support, aiming to replace mechanical ventilators. The potential application targets prematurely born neonates and neonates with life-threatening disorders. CEO Dagi Ben-Noon emphasizes the commitment to improving neonatal care.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

04/01/2024 08:00 AM

News

Inspira™ Announces $1.65 Million Registered Direct Offering of Ordinary Shares by Inspira CEO's Mother with Leading Fund Manager

Rhea-AI Summary

Inspira Technologies OXY B.H.N. (Nasdaq: IINN, IINNW) announces a strategic investment by Mr. Ronen Juster and Ms. Margi Ben-Noon. The company will issue 1,339,285 ordinary shares at $1.232 per share in a registered direct offering.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

03/25/2024 09:20 AM

News

Inspira™ Technologies Reports Full Year 2023 Financial Results

Rhea-AI Summary

Inspira Technologies OXY B.H.N. announces FDA submission for approval of INSPIRA™ ART100, 95% accuracy results for HYLA™ Blood Sensor, and granted U.S. patent, along with financial results and business developments.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-2.74%

Tags

03/18/2024 07:00 AM

News

Inspira™ Announces AMAR Regulatory Submission of the INSPIRA™ ART100, to Enter the Southeast Asia and South American Markets

Rhea-AI Summary

Inspira Technologies OXY B.H.N. announces AMAR submission for approval of the INSPIRA™ ART100, a breakthrough medical device. The company aims to redefine life support with innovative technology, potentially targeting new markets in Southeast Asia and South America.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-6.25%

Tags

03/12/2024 08:00 AM

News

Inspira™ Releases New Data Demonstrating Superiority of its Core Technology, Across Key Endpoints of HMSS Indicator

Rhea-AI Summary

Inspira Technologies achieves a breakthrough with their VORTX™ device, meeting 100% of regulatory blood oxygenation requirements with zero pressure gradient, potentially revolutionizing medical device technology. The company's U.S. patent with novel claims further enhances its innovative position in the market.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

14.17%

Tags

03/04/2024 09:20 AM

News

Inspira™ Announces Plans to Report the Primary Results for a Core Blood Oxygenation Technology Within Days

Rhea-AI Summary

Inspira Technologies OXY B.H.N. Ltd. announces a major milestone in core blood oxygenation technology with INSPIRA ART (Gen 2), aiming to revolutionize the medical device market. Anticipated FDA clearance for INSPIRA ART100 (Gen 1) in 2024 to address a $1.16 billion market.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

16%

Tags

02/27/2024 07:02 AM

News

Inspira™ To Host Conference Call to Discuss Investor Presentation and Announce Next Major Milestone

Rhea-AI Summary

Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) announces an Investor Presentation to reveal a major milestone regarding their breakthrough Augmented Respiration Technology. The technology aims to rebalance patient oxygen levels without invasive ventilation systems. The Company President, Mr. Joe Hayon, will present the details on March 4, 2024.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

FAQ

What is the current stock price of Inspira Technologies Oxy B.H.N. Ltd. Warrant (IINNW)?

The current stock price of Inspira Technologies Oxy B.H.N. Ltd. Warrant (IINNW) is $0.25 as of December 20, 2024.

What is Inspira Technologies Oxy BHN Ltd known for?

Inspira Technologies specializes in developing respiratory support technology as an alternative to mechanical ventilation.

What is the significance of OxyLink technology?

OxyLink is an advanced intravascular oxygenation apparatus that enhances blood oxygen levels and reduces carbon dioxide, facilitating effective treatment of ventilatory conditions.

What recent FDA clearance has Inspira Technologies received?

Inspira Technologies has received 510(k) class II clearance from the U.S. FDA for its INSPIRA ART100 Cardiopulmonary Bypass System.

How does the INSPIRA ART (Gen 2) system aim to revolutionize patient care?

The INSPIRA ART (Gen 2) system is designed to elevate patient oxygen levels, potentially reducing the need for mechanical ventilation and offering new treatment alternatives.

What is the core mission of Inspira Technologies?

Inspira Technologies aims to enhance patient care by developing innovative medical technologies that address critical respiratory needs and revolutionize the life support arena.